Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Molgramostim by Savara for Lung Disease: Likelihood of Approval
Molgramostim is under clinical development by Savara and currently in Phase III for Lung Disease. According to GlobalData, Phase III...
Data Insights
Risk adjusted net present value: What is the current valuation of Savara's Molgradex?
Molgradex is a recombinant protein commercialized by Savara, with a leading Phase III program in Lung Disease. According to Globaldata,...